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We have examined the functional importance of the 
two disulfide bonds  formed  by the four conserved cys- 
teines of  human interleukin (IL-6).  Using a bacterial 
expression system, we have synthesized a series of 
recombinant IL-6 mutants in which the constituent 
cysteines of the first ( C ~ s ~ ~ - C y s ~ ~ ) ,  second ( C Y S ~ ~ -  
CysS4), or both disulfide bonds of recombinant human 
interleukin-6 were replaced by other amino acids. 
Each  mutant was partially purified and tested in four 
representative bioassays. While mutants lacking 
and CysS1 retained activity similar to nonmutated re- 
combinant IL-6, the activity of mutants lacking 
and CysS4 was  significantly reduced, especially in as- 
says  involving human cell  lines. These results indicate 
that the first disulfide bond  of  human interleukin-6 is 
not required for maintenance of  normal biologic activ- 
ity. However, the fact that mutants lacking and 
Cys" were more active than corresponding cysteine- 
free mutants indicates that the disulfide bond  formed 
by these residues contributes to biologic activity in the 
absence of the second disulfide bond.  Competition bind- 
ing studies with representative mutants indicate that 
their affinity for the human IL-6 receptor parallels 
their biologic activities on human cells. 
Interleukin-6 (IL-6)' is a cytokine which plays a central 
role  in  regulation of the body's response  to injury and  infection 
(For recent reviews see Refs. 1-4). Human  IL-6 is released  by 
a number of cell types including:  B-cells, T-cells, monocytes, 
keratinocytes, endothelial cells, and  astrocytes. Biologic ac- 
tivities of IL-6 include stimulation of differentiation of B- 
cells and  T-cells,  stimulation of proliferation of hemopoietic 
stem cells, and  stimulation of release of acute-phase  reactants 
from hepatocytes. Biologically active  rIL-6  has  been xpressed 
in a number of systems including Escherichia coli, transfected 
mammalian cells, and cell-free translation  systems (5-7). 
Several  groups  have carried  out  structure-function  analysis 
on  human  IL-6 by examining  the effects of mutations  on  the 
biologic activities of rIL-6 (8-12). Using  this  approach,  it  has 
been  demonstrated  that  deletion of 28 amino acids from  the 
amino  terminus of mature  human  IL-6 does not significantly 
reduce biologic activity (8 ) ,  while deletion of three amino 
acids from the carboxyl terminus  results  in  almost  total loss 
of activity (11). We reported previously that the biologic 
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activity of human  IL-6 is abolished by internal 20-amino  acid 
deletions  anywhere  along  the  length of the  protein, with the 
exception of the  extreme  amino  terminus (12). 
The  importance of disulfide bonds in maintaining  the bio- 
logically active conformation of IL-6 is suggested by the  fact 
that  the four cysteines of human  IL-6 ( C ~ S ~ ~ ,  CysR1,C Y S ~ ~ ,  and 
Cysx4) are completely conserved in other, homologous pro- 
teins: murine and rat IL-6, human and murine granulocyte 
colony-stimulating  factor  (G-CSF),  and  chicken myelomono- 
cytic growth factor.  Furthermore,  it  has  been  demonstrated 
that  the  cysteines  in  human  IL-6 form two disulfide bonds 
(Cys4'"Cys5' a n d  C y ~ ~ ~ - C y s ' ~ )  a n d  t h a t  analogous disulfide 
bonds  are  present  in  murine  IL-6  and  human  G-CSF  (13,14). 
It  has also  been reported  that  replacement of any one of the 
cysteine residues in  human  G-CSF  causes loss of activity (15). 
In  line  with  these  findings we showed that  the  activity of a 
cysteine-free IL-6 mutant (rIL-6s) is reduced to less than 
0.1% on  human cells with respect to a nonmutated  control, 
although  this  mutant  retains ignificantly  more activity when 
tested  on mouse and  rat cell  lines (16). 
In the present study, we used our previously established 
bacterial  expression  system  to  examine  the relative functional 
importance of the two disulfide bonds of human IL-6 for 
maintenance of biologic activity. Individual disulfide bonds 
were removed by replacing pairs of cysteines with either 
nonpolar (alanine), polar (serine), or charged amino acids 
(aspartate and arginine), and the resulting mutants were 
tested  in four representative bioassays. We also  examined the 
effects of removing  disulfide bonds  on specific binding of rIL- 
6 to  human cells. We  report  here  that  mutants lacking C Y S ~ ~  
and Cys" retained  activity  similar  to a nonmutated  control 
in all of the bioassays. In contrast, biologic activity was 
decreased in  mutants lacking Cys74 and CysR4, and  this de- 
crease was greater for activity  on  human  than  on  rodent cells. 
In general, the effects of removing cysteine pairs on the 
specific binding of IL-6 mutants to human cells paralleled 
their biologic activity. Biologic activity of mutants was not 
correlated  with  the  type of amino acids  used  for substitution 
of and Cys". However, in  mutants lacking CysI4 and 
CysR4, activity was consistently highest  when cysteines were 
replaced by alanines  and lowest  when  charged  residues were 
used for substitutions. 
EXPERIMENTAL  PROCEDURES 
Construction of Genes  Encoding  rIL-6 Mutants-The  construction 
of the gene encoding rIL-GS, in which the  four  naturally occurring 
cysteines of human  IL-6  are replaced by serines,  has been  described 
previously (16). Briefly, this gene was assembled from 22 synthetic 
oligonucleotides and initially  cloned into a modified pBS M13+ 
cloning vector (Stratagene).  The  natural  stop codon of this gene was 
converted  to a serine codon by cassette mutagenesis to allow expres- 
sion  as a fusion protein. The gene encoding an IL-6 analogue with 
the  natural  pattern of cysteines  (rIL-6) was constructed by cassette 
mutagenesis of the  rIL-6S gene as described  previously (12). 
Genes  in which  individual pairs of cysteine  codons were replaced 
by pairs of serine codons were constructed by a  modification of the 
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recombinant circle  polymerase chain  reaction  method  (17). The plas- 
mids p365 and p469, which contain  the genes  encoding rIL-6s  and 
rIL-6 respectively, were each amplified with two separate  primer  sets. 
One  primer  set, designated a, was  used to amplify the  entire  length 
of each plasmid with  the  exception of the region encoding  CYS'~  and 
Cyssl (or Ser" and Ser" in  the case of p365). The products of this 
type of reaction  are  designated  as p365a or p469a, depending  on  the 
template used in  the  reaction.  In a similar  manner, p365 and p469 
were used as  templates  in a  second type of reaction using primer  set 
b to produce products p365b and p469b. These  products included the 
entire sequence of each plasmid with the exception of the region 
encoding Cys7' and CysR4 (or Ser74 and Sera4 in the case of p365). 
After gel purification, products p365a and p469b were combined, 
denatured, and annealed to produce recombinant circles with two 
single-stranded gaps. The single-stranded DNA across  the  first  gap 
encoded CYS'~  and CysS1 from p469, while the  single-stranded  DNA 
across the second gap encoded Ser" and Sera' from p365. After 
transformation into E. coli, these gapped circles were repaired to  
produce p462 which carries a gene encoding a rIL-6 protein (rIL- 
6 ~ ~ s )  in which Cys7' and Cys" have  been  replaced  by  serines. In  an 
analogous manner, p365b and p469a were annealed  and  transformed 
to  produce 643, which  encodes a rIL-6  protein (rIL-Gsscc) in which 
Mutants  in which cysteines were replaced  by alanines  or  charged 
residues were constructed  using  the  T7-GEN'"  mutagenesis  kit 
(United  States Biochemicals)  according to  instructions provided with 
the kit. To improve the yield of single-stranded DNA  needed  for the 
mutagenesis reaction, the rIL-6 gene was subcloned between the 
Hind111 and PuuI sites of M13mp19. Single-stranded  DNA was pro- 
duced  using standard procedures (18), and  mutagenic oligonucleotides 
were used to  mutate single pairs of cysteines. Mutants  in which both 
pairs of cysteines were replaced  by alanines  or  charged residues were 
produced by two  consecutive rounds of mutagenesis. 
Following sequence  verification by dideoxy  sequencing,  genes en- 
coding each of the rIL-6 variants were subcloned into the p340 
expression  vector,  which has been  described in  detail previously (12, 
16).  This vector allows high level expression of rIL-6  variants  as @- 
galactosidase  fusion proteins. 
Expression, Purification, and  Quantitation of rZL-6 Variants- 
Expression,  purification,  and  quantitation of rIL-6  variants for  use 
in bioassays was carried out as described previously (12). Briefly, 
expression vectors containing genes for IL-6 variants were trans- 
formed into  E. coli JM101.  Single ampicillin-resistant colonies were 
used to  innoculate  10-ml  broth  cultures,  and expression of the  rIL-6/ 
8-galactosidase  fusion protein was induced by addition of isopropyl 
8-D-thiogalactopyranoside (IPTG).  When @-galactosidase activity 
reached a maximum, bacteria were pelleted by centrifugation and 
stored a t  -20 "C. Bacteria were resuspended  and lysed by freezing 
and thawing following lysozyme treatment.  Lysate was sonicated to  
reduce  viscosity, and  the fusion protein,  along  with  other insoluble 
material, was pelleted by centrifugation. The pellet was washed to 
remove  soluble contaminants,  and  the fusion protein was  solubilized 
in 2% sodium  lauroyl  sarcosine.  Insoluble contaminants were removed 
by centrifugation,  and  the  fusion  protein was further purified  by  two 
rounds of selective ammonium  sulfate  precipitation. Before  bioassay 
or  quantitation,  the  IL-6  variants were cleaved from @-galactosidase 
with collagenase. Proteins were quantitated by denaturing polyacryl- 
amide gel electrophoresis under reducing conditions followed by Coo- 
massie staining  and  scanning  laser  densitometry.  For  examination of 
secondary  structure,  rIL-6  variants were denatured  in  the  presence 
or absence of 100 mM dithiothreitol prior to electrophoresis under 
denaturing  conditions  on a 15% polyacrylamide gel. 
For use in  binding  studies,  rIL-6 was  purified to  apparent  homo- 
geneity  essentially as described  previously (16). Briefly, E. coli trans- 
formed with  p478 were grown in a 10-liter  batch  culture,  induced  with 
IPTG,  and pelleted when P-galactosidase activity reached a maxi- 
mum. Fusion protein was partially purified essentially as described 
above,  except that volumes were scaled up  appropriately. After treat- 
ment with  collagenase, the majority of contaminating @-galactosidase 
was removed by selective ammonium  sulfate  precipitation. The  rIL- 
6 protein was precipitated by increasing  the  ammonium  sulfate  con- 
centration,  and  the  resulting  precipitate was  collected as a floating 
pellicle after Centrifugation. The pellicle was resuspended in 0.1% 
trifluoroacetic acid/30% acetonitrile,  and  rIL-6 was separated  from 
the remaining contaminants by reversed-phase high performance 
liquid chromatography.  Fractions  containing  rIL-6 were lyophilized 
and resuspended in  phosphate-buffered  saline  containing 0.01% (v/ 
v) Tween-20. The concentration of purified rIL-6 was determined  as 
and C y P  have  been  replaced  by serines. 
described  above  for partially purified rIL-6. 
Bioassays-Bioassays were carried  out  as described  previously  (12). 
Briefly,  cells were treated  with varying concentrations of IL-6  in 96- 
well microtiter plates. For each mutant, two or three independent 
protein  preparations were tested  in  duplicate  in  each bioassay. Hy- 
bridoma  growth factor  activity was determined by measuring  prolif- 
eration of a  mouse-mouse  hybrid cell line  (7TD1) using  colorimetric 
determination of hexosaminidase levels. B-cell differentiation activity 
was determined by measuring  IL-6  stimulated  secretion of IgM from 
a human  Epstein-Barr  virus-transformed B-cell line (SKW6.4) IgM 
was quantitated using a sandwich enzyme-linked immunosorbent 
assay  (ELISA).  Hepatocyte  stimulation  activity was determined by 
measuring  IL-6-stimulated  secretion of fibrinogen  from human  (HEP 
3B2)  and  rat (FAZA 967) hepatoma cells. Firbrinogen was quantitated 
using a  sandwich ELISA specific for human  or  rat fibrinogen. 
Quantition of biologic activities was carried  out  as described pre- 
viously. Briefly, activity  in  the  hybridoma growth  assay  was  defined 
as the  concentration of IL-6 needed to  cause  half-maximal prolifera- 
tion, while activity  in  the  hepatocyte  stimulation  and B-cell differ- 
entiation  assays was defined as  the  concentration of IL-6 needed to 
cause doubling or quadrupling of secretion of fibrinogen or IgM, 
respectively. For  calculation of activities, dose-response curves were 
plotted  on a semilogarithmic scale, and a computer  program was used 
to  fit the  approximately  linear  portion of each curve with a  second 
order polynomial. Activities for each  assay  are expressed as a per- 
centage of the  activity of nonmutated  rIL-6  in  the  same  assay. 
Radiolabeling of rZL-6-Radiolabeling of rIL-6 was carried out 
essentially  as described in Ref.  19.  Briefly,  5 pg of purified rIL-6  in 
20 pl of phosphate-buffered  saline  containing 0.01% Tween-20 was 
mixed with 20 p1  of borate buffer (0.1 M, pH 8.5) and added to 1 mCi 
= 37 MBq of dry di[12sI]iodo-Bolton and  Hunter  reagent  (20)  (Amer- 
sham).  The  mixture was incubated 30 min at  25 "C with constant 
agitation. The reaction was stopped by transferring  the  mixture  to a 
polystyrene tube  containing 100 pl of glycine (0.2 M)-NaOH buffer 
(pH 7.2). After 15-min indubation at  25 "C, the labeled IL-6 was 
purified by filtration  on a Sephadex G-10 (Aldrich) column and  the 
'251-labeled IL-6 was diluted to  a final volume of 9 ml with  binding 
buffer. After extensive dialysis against phosphate-buffered saline 
containing 10 mM NaI,  the radiolabeled rIL-6 was filter-sterilized  and 
stored at  4 "C. Denaturing polyacrylamide gel electrophoresis of the 
'2s11-IL-6 followed by autoradiography showed one band of the ex- 
pected molecular  mass. 
Binding Assays-Binding studies were performed using  a human 
monocytoid cell line (U937) (21). U937 cells were maintained in 
RPMI 1640  medium supplemented  with 10% fetal bovine serum, 100 
IU of penicillin G/ml, 100 pg of streptomycin/ml. Cells were passed 
by dilution  in  fresh  maintenance medium  when  cell densities reached 
5 X io5 cells/ml. 
Binding assays were carried out essentially as described in (19). 
Briefly,  cells were washed and  resuspended  in  binding medium a t  lo7 
cells/ml. The appropriate  amounts of labeled and unlabeled rIL-6  in 
40 pl of binding buffer were added to  100 pl of cells in a microcentri- 
fuge tube,  and  the  mixtures were  rocked at 4  "C.  After  3 h, 500 p1 of 
ice-cold binding buffer was added to each tube, and 600 p1 of the 
resulting  mixture was transferred to  another  tube  containing 800 pl 
of a mixture of  40% dioctylphthalate  and 60% dibutylphthalate. After 
centrifugation a t  10,000 X g  for  2 min,  the  supernatant was removed 
by aspiration, and  the  tips of the  tubes,  containing  the pellets, were 
cut off and  radioactivity  measured  in a y counter. Specific binding 
was measured by subtracting  the radioactivity bound  in  the  presence 
of a 200-fold excess of unlabeled  IL-6. 
The maximal binding capacity of Iz5I-IL-6 was determined as 
described previously (22) by measuring the binding of a constant 
amount of labeled IL-6 on increasing numbers of U937 cells. The 
specific radioactivity of labeled IL-6 was determined by self-displace- 
ment analysis as described previously (22). Briefly, lo6 U937 cells 
were incubated  with 203,000 cpm of Iz5I-IL-6 and various amounts of 
either unlabeled IL-6  or Iz5I-IL-6. Bound  and free  radioactivity was 
measured  after 3  h a t  4  "C. The  data were plotted  on a  semilogarithmic 
graph as the bound/free ratios versus the amounts of labeled or 
unlabeled  IL-6. The specific  radioactivity was calculated  as  the  ratio 
of the amount of radioactivity to the amount of unlabeled IL-6 
required to obtain the same bound/free ratio. For calculation of 
bound/free  ratios,  the  concentration of free ligand was determined 
by counting an aliquot of the  binding medium remaining  on  top of 
the phthalate mixture after the Centrifugation. Data for Scatchard 
analysis  and  competition  studies were generated by measuring  bind- 
ing in the presence of a constant concentration of  '2s11-IL-6 and 
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varying  concentrations of partially purified,  unlabeled rIL-6 proteins. 
Scatchard and competition data were analyzed with the LIGAND 
program (23). 
RESULTS 
Construction of Genes Encoding  rIL-6  Mutants-In order 
t o  study  the  functional role of individual disulfide bonds  in 
human  IL-6, we examined four  classes of mutants of human 
IL-6: ( a )  a mutant  containing  the four cysteines of natural 
human  IL-6 (Fig. lA); ( b )  mutants  in which all four of the 
natural cysteines were replaced by other amino acids (Fig. 
1B); ( c )  mutants  in which  only Cys45 and Cys51 were replaced 
(Fig. IC) ;  and ( d )  mutants in which only and CysR4 were 
replaced  (Fig. 1D).  Our  primary goal was to selectively pre- 
clude the formation of individual disulfide bonds without 
disrupting other structural features of the protein. It was 
therefore desirable to replace the  natural  cysteines of human 
IL-6 with an  amino acid  which  resembles cysteine  as closely 
as possible in  terms of size and chemical properties.  In  pre- 
vious structure-function studies, disulfide bonds have most 
commonly  been disrupted by replacement of cysteines  with 
alanine or serine, which resemble cysteine  in  having a  single- 
carbon side chain. However, the  polarity of the  cysteine side 
chain is intermediate between that of alanine, which is  non- 
polar  and  serine,  in which the  sulfur of the  cysteine side chain 
is replaced with a  more  electronegative oxygen. While  serine 
has been found  to replace cysteine more often  in  correspond- 
ing  proteins of homologous organisms  (24),  paired  alanines 
seem a rational choice for replacement of disulfide bonds, 
which are nonpolar. Therefore, for each of the classes of 
mutants described  above, we constructed  one  variant  in which 
the appropriate cysteines were replaced with serines and 
another  variant  in which they were replaced with  alanines. 
We also constructed a third  variant for each  class of mutants, 
in which cysteines were replaced with pairs of oppositely 
charged amino acids (aspartate and arginine). This latter 
group of mutants provided  a means of assessing  the  functional 
consequences of nonconservative  cysteine  substitutions. 
The genes encoding two of the  variants described in  this 
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FIG. 1. Schematic representation of rIL-6 variants. Protein 
chains  are  represented by thick  lines with N a n d  C designating  amino 
and carboxyl termini, respectively. Circled Letters are  standard  one- 
letter codes designating residues present  at  positions 45, 51, 74, and 
84. The relative positions of these residues with  respect  to  the  length 
of the  protein  are  not  to scale. Disulfide bonds  are  represented by 
thin Lines connecting cysteine residues. A,  nonmutated  rIL-6.  This 
protein  contains  the  pattern of cysteines  found  in  natural  human  IL- 
6. B, cysteine-free rIL-6  variants.  Cysteines were replaced with  ala- 
nines  in rIL-GA, serines  in rIL-GS, and  pairs of oppositely charged 
residues (Asp,  Arg) in  rIL-6RD. C, mutants  lacking Cys" and Cys". 
These residues were replaced with  alanines  in r1L-GAACC, serines  in 
IL-Gsscc, and charged  residues in rIL-GDRcc. D, mutants  lacking Cys74 
and Cysx4.  Residues were replaced with  alanines  in rIL-GccAA, serines 
in rIL-6rcss, and charged  residues in r I L - 6 c r ~ ~ .  
report, rIL-6 and rIL-GS, were assembled using synthetic 
oligonucleotides as described previously (12, 16).  The genes 
encoding the  other  eight  rIL-6  variants were constructed by 
mutagenesis of the genes  encoding rIL-6  and  rIL-6s.  The  rIL- 
6 protein, which contains  the four natural  cysteines of human 
IL-6, was used as a standard of comparison  in  all bioassays 
and  binding  studies. 
As described  above, one  class of rIL-6  mutants  consisted of 
three  variants which contained  no cysteines. In rIL-GA, rIL- 
6S, and rIL-6DR both pairs of cysteines were replaced by 
alanines,  serines, or aspartate-arginine  pairs, respectively. In 
the second  class of mutants,  formation of the  first disulfide 
bond was prevented by  replacing CYS*~  and Cyssl with  serines 
in rIL-Gsscc, with  alanines in r1L-GAA~c,  and  with  aspartate 
and  arginine, respectively, in ~ I L - ~ D R c c .  In  the  third class  of 
mutants, formation of the second disulfide bond was pre- 
vented by replacing  Cys74 and Cyss4 with  serines  in  rIL-G~css, 
with alanines  in  TIL-~cCAA,  and  with  aspartate  and  arginine 
respectively, in ~ I L - ~ c c D R .  
Expression  and  Characterization of IL-6  Variants-All mu- 
tants were expressed as @-galactosidase  fusion proteins  in E. 
coli. This  system allowed microgram quantities of rIL-6  to be 
expressed and  partially purified  from small  bacterial  cultures. 
The  partially purified  fusion proteins were cleaved with col- 
lagenase to release rIL-6, which could be tested directly in 
bioassays or competitive binding studies. The simplicity of 
the  purification protocol allowed testing several independent 
protein  preparations  for  each  variant. 
None of the physical properties  on which  purification  de- 
pended were noticeably altered by replacement of cysteines. 
Although we had  found previously that  deletion of some 20- 
amino acid segments of rIL-6  increased  the solubility of the 
IL-6/@-galactosidase fusion protein: this property was not 
affected by removal of cysteines. We also found that  rIL-6 
and  rIL-6S display identical  retention  times  during purifica- 
tion  to homogeneity by reversed-phase  high performance liq- 
uid  chromatography,  indicating  that  replacement of cysteines 
with  serines  did  not  alter hydrophobicity. 
In  order  to  determine  whether  appropriate disulfide bonds 
were present in our rIL-6 variants, representative proteins 
(rIL-6, ~ ~ L - ~ A A C C ,  rIL-6ccss, rIL-6s) were subjected to poly- 
acrylamide gel electrophoresis  under reducing and  nonreduc- 
ing conditions (gel not shown). Whereas the mobilities of 
these  proteins were identical  under reducing conditions,  the 
mobilities of the  cysteine-containing  variants were increased 
relative to  that of rIL-6S  under  nonreducing  conditions.  The 
apparent relative molecular masses of the nonreduced var- 
iants, based on their mobilities relative to standards, were 
22.00 for rIL-6, 22.30 for r I L - 6 A A ~ ~ ,  22.25 for IL-~ccss,  and 
22.44 for rIL-6s.  The decrease in  apparent relative  molecular 
mass of the  cysteine-containing  variants relative to  rIL-6S 
indicates  that  intramolecular disulfide bonds give these  mu- 
tants a more compact structure. As expected, this effect is 
most pronounced for rIL-6, which has  the  potential  to form 
both of the disulfide bonds present in natural IL-6. The 
absence of improper  intermolecular disulfide  bridges is indi- 
cated by the fact that the intensity of Coomassie-stained 
protein  bands was similar for reduced and nonreduced sam- 
ples and by the  absence of IL-6  multimer  bands  in nonreduced 
samples. 
Effects of Disrupting  Disulfide  Bonds  on Biologic Activity- 
The biologic activities of our rIL-6 disulfide mutants are 
summarized in Table I. Surprisingly, considering the evolu- 
tionary  conservation of cysteines in IL-6,  mutants  in which 
' J. N. Snouwaert, F. W. G. Leebeek, and Dana M. Fowlkes, 
unpublished  observation. 
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TABLE I 
Biologic activities of rIL-6  mutants as percentage  activity of rIL-6 
Mutant" FAZA 967b 7TD1' HEP 3B2' SKW6.4* 
rIL-6 100 100 100 100 
rIL-6A 
rIL-6S 
52 2 12 5.7 2 0.4 0.8 f 0.05 0.3 k 0.08 
22 2 2.5 1.07 2 0.17 0.07 f 0.007 0.02 f 0.005 
rIL-6DR 8.8 f 1.6 0.8 f 0.07 <o. 1 (0.05 
rIL-Gsscc 128 f 6.8 66 f 9.0 121 f 9.0 103 f 11 
rIL-GIlRrc 78 f 11 101 f 9.4 99 k 6.0 90 f 14 
rIL-Gcrss 39 f 8.5 9.0 f 3.3 0.7 k 0.14 0.14f 0.03 
rIL-6,,,,, 20 f 6.2 3.5 f 0.64 0.3 ? 0.08 0.06 f 0.008 
" Activities of all mutants  are given as a percentage of the  activity 
f S.E. of rIL-6, which has been  assigned an  activity of 100% in  all of 
the bioassays. For  mutants  in which activity was too low to  quantitate 
accurately, activity is given as <c, where c represents  the lowest level 
of activity which can be accurately quantitated in a given assay. 
Mutants  are  named  as described in Fig. 1. 
Activities in  the four bioassays were calculated as described under 
"Materials  and Methods." 
the c y ~ ~ ~ - C y s ~ '  disulfide  bond  was disrupted (~IL-~AAcc,  rIL- 
GSsCc, and rIL-GDRCC) had biologic activities  similar  to  those 
of the  nonmutated  control  in  all cases. There was no  consist- 
ent correlation between the  activities of these  mutants  and 
the  type of amino acid  used to replace Cys45 and Cys". 
In contrast,  the biologic activities of mutants  in which the 
C y ~ ~ ~ - c y s " ~  bond was disrupted ( ~ ~ L - ~ C C A A ,  rIL-Gccss, rIL- 
GCCDH) were significantly reduced compared  to  those of the 
nonmutated control. This reduction in activity was most 
apparent in the  assays  using  human cell lines. Whereas  the 
activities of these mutants ranged from 3.5 to 66% in the 
assays using rodent cells, their  activities ranged  from 0.06 to 
2.4% in the assays  using human cells. This species  specificity 
is similar to  that  reported previously  for rIL-6S (12). In  all 
assays, ~ I L - ~ c c A A  was more active than ~IL-~ccss ,  which in 
turn was more active  than rIL-GCCD~. Despite  the decreased 
activity caused by removal of Cys74 and Cyss4, these  mutants 
were consistently more active  than  the analogous cysteine- 
free  variants (rIL-GA,  rIL-GS, rIL-6DR). This  indicates  that, 
in  the absence of the C y ~ ~ ~ - C y s ~ ~  bond,  the C y ~ ~ ~ - C y s ~ '  bond 
does play some role in maintaining biologic activity. The 
pattern of relative biologic activities for the cysteine-free 
mutants was similar to  that described for mutants lacking 
only and CysR4; that is, for any given assay, rIL-6A was 
more active than rIL-GS, which in  turn was more active  than 
rIL-6DR. As expected, these mutants also retained signifi- 
cantly more activity  in  rodent cells (0.8-52%) than  in  human 
cells (cO.01-0.8%). 
Role of Disulfide Bonds in Binding of rIL-6 to Human 
Cells-The U937 cell line was chosen  for use in binding  studies 
for several reasons: ( a )  results obtained with a human cell 
line  are more likely to provide information  about  the  binding 
of human IL-6 to  its receptor in  uiuo; ( b )  U937 cells  have  been 
reported  to express  a  relatively  high density (2800/cell) of IL- 
6 receptors (25); ( c )  U937 cells grow rapidly in suspension, 
making  it relatively  easy to  obtain  the large numbers of cells 
needed for binding assays; and ( d )  U937 cells show relatively 
low nonspecific binding of lz5I-IL-6. The general  applicability 
of results  obtained with U937 cells to  other  types of human 
cells is  supported by the  fact  that  the  affinity of recombinant 
human IL-6 for U937 cells is similar to that measured for 
other  human cells (25). The biologic activity of IL-6 on U937 
cells, as measured by inhibition of proliferation (26), is also 
comparable,  in berms of the  minimum effective concentration 
and  the  concentration range over which the effect is observed, 
to  the  activities we measure  in HEP 3B2 and  SKW6.4 cells. 
TIL-~AA(.(. 92 f 9.7 90 f 4.7 78 f 10 109 f 11 
~ I L - ~ ~ - ( . A A  67 k 11 20 f 4.7 2.4 f 0.14 1.1 f 0.21 
Before  using lZ5I-IL-6 for Scatchard  analysis  and competi- 
tion  studies,  the  amount of bindable  protein  present in the 
'2s1-IL-6 preparation was determined,  and  its pecific activity 
was  calculated. The maximal binding  capacity was determined 
by measuring  the  binding of a constant  amount of labeled IL- 
6 to  an  increasing  number of U937 cells (22). The  extrapolated 
value of binding  to  an  infinite  number of cells indicates  that 
approximately  50% of the labeled IL-6 retained  its  ability  to 
bind specifically to U937 cells. A specific radioactivity of 
106,000 cpm/ng was measured by  self-displacement analysis 
(22), and a similar value was obtained by testing  the labeled 
IL-6 in a  hybridoma  growth assay using 7TD1 cells. 
The data for Scatchard analysis of rIL-6 binding were 
generated by incubating U937 cells in the presence of a 
constant  concentration of '251-IL-6 and increasing concentra- 
tions of unlabeled rIL-6. Scatchard  analysis of the specific 
binding of '2s1-IL-6 to  U937 cells indicated  the presence of 
3730 binding sites/cell with a Kd value of 1.2 nM. 
Because the effects of mutations  on  activity  in  human cells 
were relatively independent of the  amino  acids used to replace 
cysteines, competition studies were carried out with three 
representative  mutants: rIL-GS, rIL-6sscc, rIL-6ccss. The rel- 
ative  affinities of these  mutants for the  human IL-6 receptor 
were determined by displacement of labeled rIL-6 with  unla- 
beled mutant  proteins (Fig. 2). Kd values of each mutant were 
determined  using a curve-fitting  program (23). The  apparent 
Kd values determined for mutants were 2.9 nM for ~IL-Gsscc, 
380 nM for rIL-Gccss, and 760 nM for rIL-S. It should be noted 
that, because mutants rIL-Gccss and rIL-6S did  not completely 
inhibit binding even at  high concentrations, the standard 
error associated with the Kd values determined for these 
mutants  is relatively  large (>lo% of the  determined Kd). The 
minimum Kd values calculated for these  mutants  are 340 nM 
for rIL-Gccss and 680 nM for rIL-6s. The calculated affinities 
of these  mutants generally  paralleled their biologic activities 
on  human cells. However, it  is  interesting  to  note  that  the Kd 
of rIL-Gsscc was more than double that of the  nonmutated 
control,  despite  the  fact  that  the  activity of this  mutant was 
not reduced  relative to  the  control. 
DISCUSSION 
Native  human IL-6 forms two  disulfide  bridges which have 
been  assigned a s   C y ~ ~ ~ - C y s ~ '  and C y ~ ~ ~ - C y s ~ ~ .  The conserva- 
tion of these  cysteines  in  proteins homologous to  human IL- 
6 (murine  and  rat IL-6, murine  and  human  G-CSF, chicken 
myelomonocytic growth factor) suggests that they may be 
important in  stabilizing the biologically active  conformation 
of this cytokine. In order  to gain  a better  understanding of 
the role which disulfide bonds play in  the  function of human 
-1 1 -1 0 -9 -0 -7 
log competing IL-8 (M) 
FIG. 2. Inhibition of binding of lZ6I-IL-6 by  unlabeled rIL- 
6 variants. U937 cells (2 x IO6 cells) were incubated for 3 h a t  4 "C 
in 140 pl of binding medium containing 1 nM labeled rIL-6 and 
indicated  concentrations of rIL-6 (A), rIL-6.9 (V), ~ I L - ~ s s c c  (O), or 
rIL-Grrss (m). Each  point is the  mean of duplicate  determinations. 
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IL-6, we examined the biologic activity  and  binding  charac- 
teristics of rIL-6 mutants in which one or both pairs of 
constituent  cysteines were replaced  with other  amino acids. 
Surprisingly, removal of the  first disulfide bond by replace- 
ment of Cyd5  and Cyssl did  not significantly  affect biologic 
activity. In  contrast, replacing and Cysa caused  a sig- 
nificant decrease in activity, especially in human cells. In 
general, however, mutants containing only Cys45 and Cys" 
were more active  than analogous  cysteine-free mutants. 
The  apparently  nonessential role of the  bond 
of human IL-6 raises the question of why the constituent 
cysteine residues have been conserved in homologous cyto- 
kines through 200 million years of evolution. One possible 
explanation  is  that  this  bond  has a function  not  detected by 
our bioassays. For example, the  presence of the C y ~ ~ ~ - C y s ~ l  
bond  might increase the half-life of IL-6 in vivo by providing 
protection from degradative enzymes, either directly or by 
enhancing  binding  to a,-macroglobulin  (27). The  absence of 
such degradative  enzymes in  our bioassay system would pre- 
vent  the  detection of such  an effect. On  the  other  hand,  the 
Cys4'-Cyss' bond  might play  a role in folding or secretion of 
IL-6 from mammalian cells and would, therefore, be function- 
ally unimportant  in  our  bacterial  expression system. 
Another interesting possibility is that the first disulfide 
bond of IL-6 has been  conserved  because it  is  resistant  to l ss 
by random  mutation.  Presumably  this  bond  arose because it 
was important for activity in an ancestral cytokine which 
gave rise to IL-6, G-CSF,  and myelomonocytic  growth  factor. 
Support for this idea  comes  from  a published  report  that  the 
analogous disulfide bond  is required for biologic activity  in 
human  G-CSF (15), although  the  data  on which this  report  is 
based have not  yet  been published. If the only function of this 
bond was to stabilize the biologically active  conformation of 
the cytokine, it  is difficult to explain why this  bond  should  be 
conserved in mouse, rat,  and  human IL-6 for more  than 60 
million  years after losing this  function. Generally, the loss of 
such a  disulfide during evolution would involve substitution 
of both  constituent  cysteines  with  other residues, as exempli- 
fied in the family of serine proteases. The low statistical 
probability of mutating both cysteines simultaneously sug- 
gests  that  this  substitution process is sequential. However, if 
the presence of an  unpaired  cysteine in the or Cys" 
position of IL-6 is  detrimental  to expression or activity,  as 
has been reported for  several other engineered proteins,  than 
natural selection would prevent substitutions at either of 
these positions. Thus  it  is possible, in  theory at  least,  that a 
nonfunctional disulfide bond may have become "locked" into 
the  structure of IL-6. 
There are several possible explanations for the greater 
functional  importance of the second  disulfide bond of human 
IL-6. One  possibility is that  the second  disulfide bond  makes 
a relatively greater  contribution  to  the  thermodynamic sta- 
bility of the  active  conformation of IL-6. In  theory, disulfide 
bonds stabilize the properly folded conformation of a protein 
by lowering the  entropy of the unfolded state.  Using a previ- 
ously described method (28), it  can  be  calculated  that  the two
disulfide bonds of human IL-6 should  theoretically decrease 
the  entropy of the unfolded state by 8.1 kcal/mol at  37 "C. 
Because this stabilizing  effect increases  with  the  length of the 
loop created by a  disulfide bond,  the  theoretical decrease  in 
entropy due to the C y ~ ~ ~ - C y s * ~  bond (4.3 kcal/mol) is less 
than  that due to  the C y ~ ~ ~ - C y s ~ '  bond (3.8 kcal/mol). How- 
ever,  the relatively small difference in  the values calculated 
for  these  bonds suggests that  the  importance of the second 
disulfide arises from its  position  in  the  protein,  rather  than 
from a  general stabilization of the folded state. 
In  the absence of crystallographic data, only indirect evi- 
dence can be used to support the idea that the functional 
importance of the second  disulfide bond of IL-6 arises from 
its  particular location  in the  protein. Despite the lack of an 
x-ray  structure for IL-6, a  general structural model has been 
proposed for a group of cytokines including IL-6, based on 
similarities  in  predicted  secondary  structure,  matching loca- 
tions of known  exon boundaries,  and receptor homology (29, 
30). The  members of this group, referred  to as helical cyto- 
kines, are proposed to  adopt a conformation similar to  that 
of growth hormone and prolactin. This proposed structure 
consists of a bundle of four antiparallel (Y helices,  designated 
A to D, and  associated connections: long A-B and C-D loops 
and a short B-C loop. A putative receptor-binding surface, 
which includes parts of helix A, helix D, and  the A-B con- 
necting loop, has  been proposed for these helical cytokines 
based on mutagenic studies of growth hormone (31). If an 
analogous receptor binding region exists for IL-6, it would 
include the second disulfide bond, which would anchor  the 
receptor-binding portion of the A-B loop to helix B. In 
contrast,  the  first disulfide bond of IL-6 would be located  in 
a region of the A-B loop outside of the proposed binding 
region. Interestingly,  the region of the growth  hormone A-B 
loop which is proposed to be analogous to  the  first disulfide 
loop of IL-6 is  alternatively spliced out  at  the DNA level with 
no deleterious  effect on  structure.  One  argument  against  the 
general  applicability of this model, however, is the  fact  that 
the  first disulfide bond of G-CSF is required  for activity  (15). 
Hopefully, future  studies will help  to  better define the  under- 
lying principals governing the structure-function relation- 
ships of IL-6 and  other cytokines. 
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